Core Viewpoint - The domestic blood products industry is expected to maintain steady growth in the issuance of batches for albumin, intravenous immunoglobulin (IVIG), and fibrinogen by 2025, with an increase in the proportion of domestic albumin batch issuances compared to the previous year [1] Industry Summary - The issuance growth rate for factor VIII and prothrombin complex concentrate (PCC) is accelerating, while the issuance of rabies immunoglobulin and anti-rabies immunoglobulin is also showing good growth [1] - Due to centralized procurement and other factors, some domestic companies have adjusted the bidding prices for products like albumin and factor VIII, which is beneficial for increasing sales volume through price adjustments [1] - Companies are continuously advancing their research and development pipelines, focusing on recombinant products and new types of immunoglobulins, including chromatographic IVIG and subcutaneous immunoglobulin [1] - By 2026, the industry is advised to pay attention to the expansion of plasma stations, trends in industry mergers and acquisitions, and progress in new product development [1] - Companies that are at the forefront of the industry and are expected to continue expanding plasma station resources through both organic growth and external integration should be closely monitored for sustained growth in blood product business [1]

Group 1: Company Strategy and Growth - The company will focus on its core business of blood products, enhancing plasma supply capacity and marketing management, while actively expanding into overseas markets and improving product R&D capabilities [1] - The company aims to increase annual production capacity to over 3,000 tons following the expansion of its subsidiary, with production expected to resume in June 2025 [2][3] - The company plans to achieve a sales expense ratio of under 10% and a management expense ratio of under 7% in 2025 [2] Group 2: Product Development and Market Position - The subsidiary Guangdong Shuanglin Jiuyin is expected to obtain listing approval in 2026, while the fourth-generation intravenous immunoglobulin is anticipated to receive approval in 2027 [2] - The company expects a more than 20% year-on-year increase in plasma output in 2025 due to expanded production capacity [3] - Currently, over 60% of albumin in the market is imported, indicating potential for domestic alternatives in the future [4] Group 3: Shareholder Engagement and Financial Management - The company will implement the 2024 dividend plan promptly after approval at the annual shareholders' meeting [2] - The major shareholder will continue to support the company's development and has initiated a share buyback plan [4] - The company has maintained a high dividend payout ratio for two consecutive years and plans to continue this trend [4]

Group 1 - The blood products sector is experiencing growth, with companies like Shijiazhuang Yiling Pharmaceutical, Palin Bio, Boya Bio, and Tiantan Bio seeing stock price increases [1] - Shanxi Securities reported strong demand for immunoglobulin and albumin, with a projected market share of 6.5% and 2.5% for the company in 2023, respectively [1] - The domestic market for immunoglobulin is expanding, and the company is expected to benefit from the launch of new generation immunoglobulin products [1] Group 2 - Boya Bio aims to achieve a plasma collection of 630.6 tons in 2024, representing a year-on-year growth of 10.4%, with its main facility collecting 522.04 tons, up 11.7% [1][2] - The company is committed to compliance and operational efficiency, expecting double-digit growth in plasma collection by 2025 [1][2] - The blood products industry has not yet been included in national centralized procurement, but local and regional procurement initiatives have begun since January 2022 [2] Group 3 - Boya Bio is focusing on international expansion through product registration and technical cooperation, aiming to increase market share for immunoglobulin and factor VIII products [2] - The company is advancing innovative treatments for rare diseases, including small nucleic acids and gene therapies, to enhance its global presence [2] - The company’s president emphasized a focus on optimizing plasma utilization and enhancing product structure to improve profitability [3]